Final-Program-ATS-2023-AP.vp

50

SUNDAY • MAY 21

810 A Machine Learning-based Radiomics Model for Differentiating Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis Thorough Pyradiomics/ Y. Onodera, Yokohama, Japan 811 Lung Graph-based Machine Learning for Identification of Fibrotic Interstitial Lung Diseases/ H. Sun, Beijing, China 812 Development and Validation of a CT-based Deep Learning Algorithm to Augment Non-invasive Diagnosis of Idiopathic Pulmonary Fibrosis/ M. Maddali, Stanford, CA 813 Deep Learning and Artificial Intelligence Based Optical Coherence Tomography for Quantifying Microscopic Disease Burden in Interstitial Lung Disease/ S. Nandy, Boston, MA 814 AI Techniques to Differentiate Between Sub-Groups of Diffuse Cystic Lung Diseases Using Phenotypic Characteristics/ R.T. Hearne, Belfield, Ireland 815 Mapping of Collagen Organization in Pulmonary Fibrosis In Vivo Using Optic Axis-resolved Polarization Sensitive Optical Coherence Tomography/ J. Lee, Boston, MA 816 Computed Tomography Pulmonary Fat Attenuation Volume (ctP fav ) as a Novel Biomarker of Idiopathic Pulmonary Fibrosis/ M. O’Callaghan, Dublin, Ireland 817 The Automated E-ILD CT Algorithm Is More Prognostic Than FVC in the Serial Assessment of Patients With Non-IPF Fibrotic Interstitial Lung Disease/ P.M. George, London, United Kingdom 818 Imaging Signature Idiopathic Pulmonary Fibrosis (IS IPF): An Analytic Validation Study of Two CT Image-based Biomarkers in an Independent Cohort for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis/ G.H.J. Kim, Los Angeles, CA 819 Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the IINPULSIS Trials/ J. Jacob, London, United Kingdom 820 IgM Rheumatoid Factor Is Associated With ILD-related Hospitalization and Death in the Multi-ethnic Study of Atherosclerosis (MESA)/ S. Levsky, New York, NY 821 Association of Circulating Complement Pathway Gene Expression With Progression of Idiopathic Pulmonary Fibrosis/ A.C. Swaminathan, Durham, NC 822 Changes in Complement Pathway Gene Expression in the Lung Tissue of Patients With Pulmonary Fibrosis With and Without an Acute Exacerbation/ A.C. Swaminathan, Durham, NC 823 Dynamic Changes in Hyperpolarized 129 Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function/ A.C. Swaminathan, Durham, NC

313 Black Individuals With Sarcoidosis Have Significant Delays in Referral/ O.A. Akhiwu, Baltimore, MD 314 Sleep Disparities Among Sexual Minority Early Adolescents: The Mediating Role of Sexual Identity-based Discrimination/ J.-M. Bruzzese, New York, NY

CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

A23

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Room 209 A-C (Level 2)

Poster Viewing

9:00-9:45

Discussion 9:45-11:00 Chairing: P.L. Molyneaux, MD, FRCP, PhD, London, United Kingdom G.H.J. Kim, PhD, MS, Los Angeles, CA M.L. Salisbury, MD, MS, Nashville, TN 801 Plasma Metabolomics and Quantitative Interstitial Abnormalities in Ever-smokers/ B. Choi, Boston, MA 802 Exploring the Causal Effects of Circulating Galectin-3 and sRAGE on Interstitial Lung Abnormalities Risk: A Mendelian Randomization Study/ R. Sangani, Boston, MA 803 Proteins Associated With Interstitial Lung Abnormalities in Relatives of Patients With Pulmonary Fibrosis/ J.A. Rose, Boston, MA 804 Antinuclear Antibodies and Progression of High Attenuation Areas on Chest Computed Tomography: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/ K.F. Flack, Philadelphia, PA 805 Airway Tree Caliber and Subclinical Interstitial Lung Disease in Community-dwelling Adults: The Multi-ethnic Study of Atherosclerosis (MESA)/ K. Berger, New York, NY 806 New Quantitative Metric for Identifying Fibrosis Predicts Lung Cancer Outcomes in the National Lung Screening Trial/ J.M. Wang, Ann Arbor, MI 807 Endobronchial Optical Coherence Tomography to Assess Small Airway Involvement in Early IPF/ S.R. Berigei, Boston, MA 808 Machine Learning of Plasma Proteomics for Differential Diagnosis of Interstitial Lung Disease/ Y. Huang, Charlottesville, VA 809 Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Data From the INBUILD Trial/ I. Noth, Charlottesville, VA

ATS 2023 • Washington, DC